Equities
Golar LNG earnings in focus as FLNG project pipeline expands
Floating LNG producer Golar LNG reports quarterly results amid a growing global fleet of floating liquefaction units.
McGraw Hill shares rise on strong earnings outlook
Publisher reports better-than-expected quarterly results and lifts full-year guidance, driving a 6% intraday gain.
Collegium Pharmaceutical shares rise on strong Q2 earnings
The specialty pharmaceutical company reported better-than-expected second-quarter results and raised its full-year guidance, lifting shares by over 5% in early trading.
Bending Spoons shares fall as revenue growth slows
Italian software firm’s stock declines after preliminary Q2 results miss expectations on revenue and profit margins.
Jefferies upgrades Five Below to buy, cites potential TJX-like re-rating
Analyst upgrades discount retailer to buy, citing operational improvements and valuation upside similar to TJX Companies. Target raised to $75 from $65.
Wolverine World Wide shares rise on strong quarterly results
Footwear maker Wolverine World Wide reports better-than-expected revenue and profit for the latest quarter, lifting its stock by over 5% in premarket trading.
X Energy shares rise after analyst upgrades to buy
Stock gains after Jefferies upgrades X Energy to buy from hold, citing improved market outlook and operational progress.
SanDisk outlines investment strategy at investor day
Company details capital allocation plans, product roadmap and operational priorities amid shifting memory market dynamics.
Wolfe Research lifts Biogen, AbbVie to buy on pipeline, valuation
Analysts cite robust drug pipelines and discounted valuations as reasons for the upgrades. Shares of both biotech firms rise in premarket trading.
Bernstein flags top electrical equipment stocks for data center demand
Analysts highlight stocks poised to benefit from surging infrastructure spending tied to AI and cloud computing growth.
Norway's wealth fund flags erosion in shareholder rights
Norges Bank Investment Management warns of weakening corporate governance standards globally, threatening long-term investor interests.
Darden Restaurants shares hit 52-week high at $221
The casual dining operator’s stock reached its highest level since mid-2023, extending a multi-month rally amid strong same-store sales and cost discipline.
Immunovant shares hit 52-week high of $41.37
Immunovant’s stock surged to a fresh 52-week peak, extending gains amid biotech sector momentum.
Grasim posts 24th straight quarterly revenue growth, expands new ventures
India’s diversified conglomerate reports Q1 FY27 revenue increase as new business units scale operations. Aditya Birla Group unit posts 24th consecutive quarterly growth.
Aptevo raises $4.5M via warrant exercises and private placement
Biotech firm Aptevo secures $4.5 million through warrant conversions and a private funding round, bolstering its cash position for R&D and operations.
Octave Q2 2026 presentation highlights ARR growth amid revenue shift
Software firm Octave reports second-quarter 2026 annual recurring revenue growth as it navigates a transition in its revenue mix.
Liquidia Q2 2026 slides show YUTREPIA sales up 31%, 10 studies underway
YUTREPIA revenue growth accelerates in Q2 2026 as Liquidia advances 10 clinical studies, including Phase 3 trials for pulmonary arterial hypertension.
Dyne Therapeutics shares hit 52-week high of $27.19
Biotech firm Dyne Therapeutics advances 2.1% to its highest level since mid-2023 as shares extend recent gains amid broader sector strength.
Septerna Inc shares reach record $50 as biotech surges
Biotech firm Septerna Inc hit a new all-time high of $50 on Tuesday, extending gains amid broader sector momentum.
Tencent Q2 2026 revenue rises as AI investment accelerates
Chinese tech giant reports solid growth in core segments while increasing spending on artificial intelligence infrastructure.
Bragg Q2 2026 results show revenue drop, margin gains; Drayton deal finalized
Bragg reported a 12% year-over-year decline in revenue for Q2 2026 despite margin expansion, while the acquisition of Drayton closed as scheduled.
ADC Therapeutics Q2 2026 costs fall but FDA concerns weigh on shares
Costs decline in ADC Therapeutics' Q2 2026 presentation, but regulatory scrutiny from the FDA tempers investor sentiment.
Oracle shares fall 42% in a year as AI hype meets credit concerns
Credit risk rises at Oracle while Nebius benefits from AI-related demand. One-year stock performance diverges sharply amid shifting investor priorities.
Air Canada forecasts strong fall demand despite rising costs
Airline expects robust seasonal travel despite ongoing cost pressures from fuel and labor expenses. Third-quarter outlook remains positive.